Resveratrol Antagonizes EGFR-Dependent Erk1/2 Activation in Human Androgen-Independent Prostate Cancer Cells with Associated Isozyme-Selective PKCα Inhibition (original) (raw)
References
Yang CS, Landau JM, Huang M-T, Newmark HL: Inhibition of carcinogenesis by dietary polyphenolic compounds. Annu Rev Nutr 21: 381–406, 2001 Google Scholar
Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CWW, Fong HHS, Farnsworth NR, Kinghom AD, Mehta RG, Moon RC, Pezzuto JM: Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275: 218–220, 1997 Google Scholar
Gusman J, Malonne H, Atassi G: A reappraisal of the potential chemopreventive and chemotherapeutic properties of resveratrol. Carcinogenesis 22: 1111–1117, 2001. Google Scholar
Subbaramaiah K, Chung WJ, Michaluart P, Telang N, Tanabe T, Inoue H, Jang M, Pezzuto JM, Dannenberg AJ: Resveratrol inhibits cyclooxygenase-2 transcription and activity in phorbol ester-treated human mammary epithelial cells. JBC 273: 21875–21882, 1998 Google Scholar
Mutoh M, Takahashi M, Fukuda K, Matsushima-Hibiya Y, Hiroshi Mutoh H, Sugimura T, Wakabayashi K: Suppression of cyclooxygenase-2 promoter-dependent transcriptional activity in colon cancer cells by chemopreventive agents with a resorcin-type structure. Carcinogenesis 21: 959–963, 2000. Google Scholar
Sgambato A, Ardito R, Faraglia B, Boninsegna A, Wolf FI, Cittadini A: Resveratrol, a natural phenolic compound, inhibits cell proliferation and prevents oxidative DNA damage. Mutat Res 496: 171–180, 2001 Google Scholar
Hsieh T-C, Wu JM: Differential effects on growth, cell cycle arrest, and induction of apoptosis by resveratrol in human prostate cancer cell lines. Exp Cell Res 249: 109–115, 1999 Google Scholar
Schneider Y, Vincent F, Duranton B, Badolo L, Gossé F, Bergmann C, Seiler N, Raul F: Anti-proliferative effect of resveratrol, a natural component of grapes and wine, on human colonic cancer cells. Cancer Lett 158: 85–91, 2000 Google Scholar
Lara PN, Jr., Meyers FJ: Treatment options in androgen-independent prostate cancer. Cancer Inves 17: 137–144, 1999 Google Scholar
Scher HI, Sarkis A, Reuter V, Cohen D, Netto G, Petrylak D, Lianes P, Fuks Z, Mendelsohn J, Cordon-Cardo C: Changing pattern of expression of the epidermal growth factor receptor and transforming growth factor alpha in the progression of prostatic neoplasms. Clin Cancer Res 1: 545–550, 1995 Google Scholar
Jones HE, Eaton CL, Barrow D, Dutkowski CM, Gee JMW, Griffiths K: Comparative studies of the mitogenic effects of epidermal growth factor and transforming growth factor-and the expression of various growth factors in neoplastic and non-neoplastic prostatic cell lines. Prostate 30: 219–231, 1997 Google Scholar
Prewett M, Rockwell P, Rockwell RF, Giorgio NA, Mendelsohn J, Scher HI, Goldstein NI: The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma. J Immunother Emphasis Tumor Immunol 19: 419–427, 1996 Google Scholar
Hofer DR, Sherwood ER, Bromberg WD, Mendelsohn J, Lee C, Kozlowski JM: Autonomous growth of androgen-independent human prostatic carcinoma cells: role of transforming growth factor alpha. Cancer Res 51: 2780–2785, 1991 Google Scholar
Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, Bartsch G, Klocker H: Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res. 54: 5474–5478, 1994 Google Scholar
Robinson MJ, Cobb MH: Mitogen-activated protein kinase pathways. Curr Opin Cell Biol 9: 180–186, 1997 Google Scholar
Putz T, Culig Z, Eder IE, Nessler-Menardi C, Bartsch G, Grunicke H, Überall F, Klocker H: Epidermal growth factor (EGF) receptor blockade inhibits the Action of EGF, insulin-like growth factor I, and a protein kinase A activator on the mitogen-activated protein kinase pathway in prostate cancer cell lines. Cancer Res 59: 227–233, 1999 Google Scholar
Yeh S, Lin H-K, Kang H-Y, Thin TH, Lin M-F, Chang C: From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. PNAS 96: 5458–5463, 1999 Google Scholar
Gioeli D, Mandell JW, Petroni GR, Frierson HF, Jr., Web MJ: Activation of mitogen-activated protein kinase associated with prostate cancer progression. Cancer Res 59: 279–284, 1999 Google Scholar
Price D, Rocca G, Gou C, Ballo M, Schwinn D, Luttrell L: Activation of extracellular signal-regulated kinase in human prostate cancer. J Urol 162: 1537–1542, 1999 Google Scholar
Chen N, Ma W-Y, She Q-B, Wu E, Liu G, Bode AM, Dong Z: Transactivation of the epidermal growth factor receptor is involved in 12-_O_-Tetradecanoylphorbol-13-acetate-induced signal transduction. JBC 276: 46722–46728, 2001. Google Scholar
Newton AC: Regulation of protein kinase C. Cur Opin Cell Biol 9: 161–167, 1997 Google Scholar
Stewart JR, Ward NE, Ioannides CG, O'Brian CA: Resveratrol preferentially inhibits protein kinase C-catalyzed phosphorylation of a cofactor-independent, arginine-rich protein substrate by a novel mechanism. Biochemistry 38: 13244–13251, 1999 Google Scholar
Stewart JR, Christman KL, O'Brian CA: Effects of resveratrol on the autophosphorylation of phorbol ester-responsive protein kinases: inhibition of protein kinase D but not protein kinase C isozyme autophosphorylation. Biochem Pharmacol 60: 1355–1359, 2000 Google Scholar
Ács P, Bögi K, Marquez AM, Bíró T, Szállási Z, Blumberg PM: The catalytic domain of protein kinase C chimeras modulates the affinity and targeting of phorbol ester-induced translocation. JBC 272: 22148–22153, 1997 Google Scholar
Ogretmen B, Schady D, Usta J, Wood R, Kraveka JM, Luberto C, Birbes H, Hannun YA, Obeid LM: Role of ceramide in mediating the inhibition of telomerase activity in A549 human lung adenocarcinoma cells. JBC 276: 24901–24910, 2001 Google Scholar
Gupta KP, Ward NE, Gravitt KR, Bergman PJ, O'Brian CA: Partial reversal of multidrug resistance in human breast cancer cells by an _N_-myristoylated protein kinase C-α pseudosubstrate peptide. JBC 271: 2102–2111, 1996 Google Scholar
De Miguel P, Royuela, Bethencourf R, Ruiz, Fraile, Paniagua: Immunohistochemical comparative analysis of transforming growth factor, epidermal growth factor, and epidermal growth factor receptor in normal, hyperplastic and neoplastic human prostates. Cytokine 11: 722–727, 1999 Google Scholar
Gou C, Luttrell L, Price D: Mitogenic signaling in androgen sensitive and insensitive prostate cancer cell lines. J Urol 163: 1027–1032, 2000 Google Scholar
Payne DM, Rossomando AJ, Martino P, Erickson AK, Her JH, Shabanowitz J, Hunt DF, Weber MJ, Sturgill TW: Identification of the regulatory phosphorylation sites in pp42/mitogen-activated protein kinase (MAP kinase). EMBO J 10: 885–892, 1991 Google Scholar
Sturgill TW et al.: Nature 334: 715–718, 1988 Google Scholar
Kolch W, Heldecker G, Kochs G, Hummel R, Vahidi H, Mischak H, Finkenzeller G, Marme D, Rapp UR: Protein kinase C activates RAF-1 by direct phosphorylation. Nature 364: 249–252, 1993. Google Scholar
Miranti CK, Ohno S, Brugge JS: Protein kinase C regulates integrin-induced activation of the extracellular regulated kinase pathway upstream of Shc. JBC 274: 10571–10581, 1999 Google Scholar
Comford P, Evans J, Dodson A, Parsons K, Woolfenden A, Neoptolemos J, Foster CS: Protein kinase C isoenzyme patterns characteristically modulated in early prostate cancer. Am J Pathol 154: 137–144, 1999 Google Scholar
Ron D, Kazanietz M: New insights into the regulation of protein kinase C and novel phorbol ester receptors. FASEB J 13: 1658–1676, 1999. Google Scholar
Matthews SA, Rozengurt E, Cantrell D: Characterization of serine 916 as an in vivo autophosphorylation site for protein kinase D/protein kinase C_μ_. JBC 274: 26543–26549, 1999 Google Scholar
Vertommen D, Rider M, Ni Y, Waelkens E, Merlevede W, Vandenheede JR, Van Lint J: Regulation of protein kinase D by multisite phosphorylation: identification of phosphorylation sites by mass spectrometry and characterization by site-directed mutagenesis. JBC 275: 19567–19576, 2000 Google Scholar
Ahmad N, Adhami VM, Afaq F, Feyes DK, Mukhtar H: Resveratrol causes WAF-1/p21-mediated G1-phase arrest of cell cycle and induction of apoptosis in human epidermoid carcinoma A431 Cells. Clin Cancer Res 7: 1466–1473, 2001 Google Scholar
Mouria M, Gukovskaya AS, Jung Y, Buechler P, Hines OJ, Reber HA, Pandol SJ: Food-derived polyphenols inhibit pancreatic cancer growth through mitochondrial cytochrome C release and apoptosis. Int J Cancer 98: 761–769, 2002. Google Scholar
Gehm BD, McAndrews JM, Chien P-Y, Jameson JL: Resveratrol, a polyphenolic compound found in grapes and wine, is an agonist for the estrogen receptor. PNAS 94: 14138–14143, 1997 Google Scholar
Bhat KPL, Lantvit D, Christov K, Mehta RG, Moon RC, Pezzuto JM: Estrogenic and antiestrogenic properties of resveratrol in mammary tumor models. Cancer Res 61: 7456–7463, 2001 Google Scholar
Mgbonyebi OP, Russo J, Russo IH: Antiproliferative effect of synthetic resveratrol on human breast epithelial cells. Int J Oncol 12: 865–869, 1998 Google Scholar
Mitchell SH, Zhu W, Young CYF: Resveratrol inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells. Cancer Res 59: 5892–5895, 1999 Google Scholar
Logothetis CJ: Docetaxel in the integrated management of prostate cancer. Current applications and future promise. Oncology 16: 63–72, 2002 Google Scholar
Karashima T, Sweeney P, Slaton JW, Kim SJ, Kedar D, Izawa JI, Fan Z, Pettaway C, Hicklin DJ, Shuin T, Dinney CP: Inhibition of angiogenesis by the antiepidermal growth factor receptor antibody ImClone C225 in androgen-independent prostate cancer growing orthotopically in nude mice. Clin Cancer Res 8: 1253–1264, 2002. Google Scholar
Sirotnak FM, Zakowski MF, Miller VA, Scher HI, Kris MG, Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 6: 4885–4892, 2000 Google Scholar